Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.

September 2, 2015

Frontline Therapy Setting

Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges and gaps in the current standards of care of patients with multiple myeloma, including oral and intravenous treatment options in the frontline therapy setting.

December 3, 2013

The Impact of Hedgehog Pathway Inhibitors on the Management of Patients with Basal Cell Carcinoma

In this third WCMC clinical commentary entitled, Basal Cell Carcinoma Case Studies in Hedgehog Pathway Inhibition Radiation, Joel Claveau, MD, CSPQ, FRCPC; Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD and Aleksandar Sekulic, MD, PhD discuss different case studies where patients were successfully treated by Hedgehog Pathway Inhibitors.